Stopping or continuing riociguat after successful lung angioplasty
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial compares what happens when people with chronic thromboembolic pulmonary hypertension (CTEPH) either stop or continue taking the medication riociguat after they have done well following a procedure called balloon pulmonary angioplasty. The goal is to learn whether it is safe and better to stop the medication or keep taking it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have a type of high blood pressure in the lungs called CTEPH that was treated with a procedure called balloon pulmonary angioplasty, and you are now feeling well (able to do most daily activities with little or no symptoms).
- You have been taking the medication riociguat for at least 6 months, and the dose has been the same for at least 3 months.
- Your last balloon angioplasty procedure was at least 6 months ago.
- You can walk at least 150 meters (about half a football field) in 6 minutes.
- If you are a woman who could become pregnant, you must agree to use reliable birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a minimally invasive procedure called balloon pulmonary angioplasty (BPA) helps patients with chronic blood clots in the lungs improve their heart function and overall recovery. Researchers will measure blood flow patterns in your arteries before and after the procedure to understand how well your heart recovers.
This trial is for people with a type of long-term blood clot in the lungs (CTEPH) who have been taking riociguat for at least 12 weeks. It will see what happens when the medication is stopped, focusing on how the right side of the heart is doing.
This trial tests switching from sildenafil to a newer medicine called riociguat for people with CTEPH (a type of lung blood pressure problem) who still have symptoms after a balloon procedure. The goal is to see if the switch helps them feel better.
This study looks at how well a medicine called riociguat works for people with pulmonary arterial hypertension when they switch to it from another similar medicine (a PDE5 inhibitor) while already taking two other blood vessel-relaxing medicines. The goal is to see if the switch helps improve their condition over 6 months.
This trial tests whether a procedure called balloon pulmonary angioplasty is safe and effective for people with chronic thromboembolic disease in the lungs, especially when surgery isn’t an option. If you have CTEPH, it may help improve lung blood flow and symptoms.
This study tests whether people with pulmonary arterial hypertension (PAH), a type of high blood pressure in the lungs, can safely stop taking the medication sotatercept after being on it for at least 6 months and doing well. It aims to see if those who stop can maintain their health without the drug.
Hear when a new CTEPH trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.